MT027 Allogeneic CAR-T

MT027 CAR-T · T-MAXIMUM Pharmaceutical Inc

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MT027 Allogeneic CAR-T, covering 2026-02-10 to 2026-02-10. Get the full timeline:

Most recent: Clinical Trial Update: The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma [Phase 2]